What we deliver

From evidence dossiers to advisory boards, every service is built to turn complex scientific work into practical, expert-validated deliverables for pharma teams.

Services for

Medical Affairs → Market Access → Brand & Launch → Regional Teams →

All

Medical Affairs

Market Access

Brand & Launch

Regional Teams

All

Pre-Launch

Launch

Mature Brand

Any Stage

All

Access & Localization

Evidence Generation

Launch Support

KOL & Expert Engagement

Congress & Publications

Omnichannel Content

14 services shown

Evidence & Medical Writing

Evidence Dossiers

Structured evidence packages adapted for your local market — local comparators, treatment guidelines, and clinical data reframed for affiliate medical and access teams across EMEA.

Medical AffairsMarket AccessRegional

See cases → Learn more →

Clinical Summaries

Concise, field-ready summaries of key clinical trial data — designed for Medical Science Liaisons, medical directors, and internal pharma teams.

Medical Affairs

See cases → Learn more →

Medical Writing

Publication-grade manuscripts, congress abstracts, scientific posters, and regulatory documents — written by MDs and PhDs with deep therapeutic area expertise.

Medical Affairs

See cases → Learn more →

Evidence Communication

Visual abstracts, medical infographics, interactive slide decks, and omnichannel content — transforming complex clinical data into accessible formats for every stakeholder.

Medical AffairsBrand & Launch

See cases → Learn more →

Literature Monitoring

Systematic literature surveillance and rapid post-congress/post-publication updates via PubMed and medical databases — keeping your evidence base current.

Medical Affairs

See cases → Learn more →

Market Access & Value

Payer Dossiers

Country-specific value dossiers, HTA submissions, AMCP-format dossiers, and payer-facing evidence packages — adapted for local health technology assessment requirements.

Market Access

See cases → Learn more →

KOL & Expert Engagement

Advisory Boards

End-to-end advisory board management and Delphi consensus projects — from KOL recruitment and protocol design to transcripts, summary reports, and publication-ready outputs.

Medical Affairs

See cases → Learn more →

KOL Programmes

Structured KOL engagement strategies — speaker programmes, expert mapping, scientific collaboration, and relationship management across therapeutic areas and markets.

Medical AffairsBrand & Launch

See cases → Learn more →

Launch & Strategy

Launch Evidence Toolkit

Complete pre-launch evidence package — core scientific narrative, MSL slide decks, payer FAQ documents, and KOL briefing materials, aligned across functions from day one.

Brand & LaunchMedical Affairs

See cases → Learn more →

Publication Planning

End-to-end publication strategy — author coordination, target journal selection, manuscript submission management, and timeline tracking for pharma publication plans.

Medical Affairs

See cases → Learn more →

Presentations & Content

Slide Decks

From literature search to final polished design — scientific presentations in any format: PPTX, HTML, interactive quizzes. Professional redesign with unified pharma branding and data visualization.

Medical AffairsBrand & Launch

See cases → Learn more →

Source Verification

Reference sourcing, fact-checking, and scientific annotation for pharma material approval (MLR review) systems. Ensuring every claim is traceable, accurate, and compliance-ready.

Medical Affairs

See cases → Learn more →

Data & Real-World Evidence

Biostatistics

Clinical dataset analysis, data cleaning, statistical programming, and data extraction from large unstructured sources including EHR, physician notes, and medical registries.

Medical AffairsMarket Access

See cases → Learn more →

RWD/RWE Studies

Full-service RWE support from protocol synopsis to final publication — AI-enhanced EDC setup, observational study design, real-world data collection, statistical analysis, and reporting.

Medical AffairsMarket Access

See cases → Learn more →

Real work. Measurable outcomes.

Selected case studies

View all →

OncologyEvidence Dossier

Ribociclib post-ASCO update: field-ready summary for 12 EMEA markets in 48 hours

✓ MSL teams received updated materials within 48h of congress close

OncologyAdvisory Board

Delphi consensus on treatment sequencing — 5 scientific societies endorsed

✓ 5 scientific societies endorsed the consensus document

Rare DiseasePatient Programme

PKU patient identification: diagnosed patients doubled within 12 months

✓ Diagnosed patients doubled within 12 months of launch

Evidence Scanner^TM

AI infrastructure

AI-powered.
Expert-validated.

We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.

Research

Structured PubMed queries with narrative or table outputs

Monitoring

Weekly literature digests by drug, target, or topic

AI-Enhanced EDC

Electronic data capture with AI-assisted structuring of unstructured records

Fact-Checker

Claim verification against your source documents

AI accelerates. Our experts validate.

Every output goes through expert medical review before it reaches your team. AI handles structure and speed — we handle scientific judgement and MLR readiness.

Explore Evidence Scanner → Request a demo

Evidence Scanner™ · Research module

// Query: ribociclib OS data MONALEESA 2023–24

search("ribociclib overall survival", {

years: [2023, 2024],

output: "structured_table"

})

// 847 records → 23 relevant

Processing 847 records...

Evidence Summary

MONALEESA-2 updated OS (NEJM 2023): median OS 63.9 mo vs 51.4 mo (HR 0.76, 95% CI 0.63–0.93). Benefit maintained across all pre-specified subgroups...

Need a specific
deliverable?

Tell us what you're working on — we respond within 24 hours with a tailored scope and timeline.

Book a scoping call See case studies first

SolveLetter · Monthly insights